Preventing VTE in Cancer, Maintaining Low Bleeding Risk: Reduced-Dose Apixaban
Mario Balsa, medical oncology resident at Institut Català d’Oncologia, shared an insightful post on X:
” ‘New’ The New England Journal of Medicine (NEJM) study in 1,766 patients with cancer-associated VTE:
- Reduced-dose apixaban (2.5mg BID) vs full dose (5mg BID)
- VTE recurrence: 2.1% vs 2.8%
- Clinically relevant bleeding: 12.1% vs 15.6%
Same protection, less bleeding. Sometimes, less really is more!”
Effects of reduced dose of an oral anticoagulant on thromboembolic events and bleeding are discussed in the new study ”Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism” published by Isabelle Mahé et al. in the New England Journal of Medicine (NEJM).
In patients with active cancer and venous thromboembolism, extended treatment with reduced-dose apixaban was as effective as the full dose in preventing recurrent events.
Moreover, dose reduction resulted in fewer bleeding complications.
This supports reduced-dose apixaban as a safer alternative for long-term anticoagulation in this population.
Never miss the scientific advancements in the World of Hematology, read Hemostasis Today.
-
Oct 24, 2025, 11:46Rocío Vacik Díaz on Impact of LVAD Implantation at ECTH 2025
-
Oct 23, 2025, 06:03Melanie Daniel: Wonderful Presentation on Emicizumab by Mickael Rosa at ECTH
-
Oct 22, 2025, 06:17We Will Continue to Raise Awareness and Remind Rveryone That Donating Blood Means Saving Lives - Yeolyan Hematology and Oncology Center
-
Oct 21, 2025, 06:59Samwel Mikaye: Polycythemia and the Risk of Blood Clots
-
Oct 21, 2025, 06:58Samuel Nweke: Interpreting D-Dimer Results
-
Oct 24, 2025, 12:08Julián Alejandro Rivillas Compares Tenecteplase to Low-dose Alteplase: TRACE-5 Interim Phase II Results
-
Oct 24, 2025, 12:03Melissa Glasner on Integration of Gene Therapy Into Hemophilia Care
-
Oct 24, 2025, 11:41Yaping Zhang on Platelet Adhesion Receptors
-
Oct 24, 2025, 11:37Omid Jafari and Colleagues Present the VTE-BERT Natural Language Processing Model
-
Oct 24, 2025, 11:34Insights on IV Thrombolysis and Mechanical Thrombectomy from Benjamin Maier and Colleagues
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 21, 2025, 06:58Arno Nierich: How Caffeine Affects Red Blood Cells and Blood Storage
-
Oct 21, 2025, 06:43Could Gene Therapy Offer Lasting Quality of Life for People with Hemophilia B?
-
Oct 24, 2025, 11:28Louise Bannon and Thomas Reiser Thank World Thrombosis Day Supporters Around The World
-
Oct 24, 2025, 10:48Melanie Daniel Congratulates Mickael Rosa and Antoine Rauch on Winning Bernd R. Binder Prize
-
Oct 24, 2025, 10:47Nan van Geloven Was Awarded The Prestigious Vidi Grant
-
Oct 23, 2025, 06:52Louise Bannon: Thrilled to Witness The Incredible Reach of This Year's World Thrombosis Day!
-
Oct 23, 2025, 06:50Caitlin Raymond to Speak at The 11th Annual Bloodless Medicine and Surgery Society Conference